Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

被引：26
作者：
Albers, Lawrence James [2 ]
Musenga, Alessandro [1 ]
Raggi, Maria Augusta [1 ]
机构：
[1] Univ Bologna, Dept Pharmaceut Sci, Lab Pharmacotoxicol Anal, I-40126 Bologna, Italy
[2] Univ Calif Irvine, Dept Psychiat, Long Beach, CA 90822 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2008年 / 17卷 / 01期
关键词：
atypical antipsychotic; iloperidone; pharmacodynamics; pharmacokinetics; schizophrenia treatment; therapeutic drug monitoring;
D O I：
10.1517/13543784.17.1.61
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Iloperidone is a new-generation atypical antipsychotic agent, acting as a serotonin/dopamine (5-HT2A/D-2) antagonist, under development by Vanda Pharmaceuticals for the treatment of schizophrenia, bipolar disorder and other psychiatric conditions. Chemically, iloperidone is a benzisoxazole, like risperidone, and shows a multiple receptor binding profile, sharing this feature with the other atypical antipsychotic agents. Administered orally, the drug is highly bound to plasma proteins and extensively metabolised. Several clinical trials have been carried out, to check efficacy, safety and side effects. in order to introduce iloperidone as an agent for the treatment of schizophrenia, a short overview of the disease and of the most important antipsychotic drugs available or under development will be reported. Iloperidone pharmacokinetics and pharmacodynamics are presented herein, together with an evaluation of clinical safety and efficacy results.
引用
收藏
页码：61 / 75
页数：15
相关论文
共 77 条
  • [1] Pharmacotherapy of Schizophrenia: The Past, Present and Future
    Akhondzadeh, Shahin
    [J]. CURRENT DRUG THERAPY, 2006, 1 (01) : 1 - 7
  • [2] Pharmacogenomic-guided rational therapeutic drug monitoring: Conceptual framework and application platforms for atypical antipsychotics
    Albers, LJ
    Ozdemir, V
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) : 297 - 312
  • [3] Side effects of atypical antipsychotic drugs
    Ananth, J
    Parameswaran, S
    Gunatilake, S
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (18) : 2219 - 2229
  • [4] Central 5-HT2A and D-2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men
    Andree, B
    Halldin, C
    VrijmoeddeVries, M
    Farde, L
    [J]. PSYCHOPHARMACOLOGY, 1997, 131 (04) : 339 - 345
  • [5] [Anonymous], PSYCHOPHARMACOLOGY A
  • [6] Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats
    Auclair, Agnes L.
    Galinier, Alexandra
    Besnard, Joel
    Newman-Tancredi, Adrian
    Depoortere, Ronan
    [J]. PSYCHOPHARMACOLOGY, 2007, 193 (01) : 45 - 54
  • [7] BAROLDI P, 2007, PHARMACOKINETIC PK P
  • [8] Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats
    Barr, Alasdair M.
    Powell, Susan B.
    Markou, Athina
    Geyer, Mark A.
    [J]. NEUROPHARMACOLOGY, 2006, 51 (03) : 457 - 465
  • [9] Cost-effectiveness analysis of schizophrenia relapse prevention -: An economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain
    Bernardo, Miguel
    Azanza, Jose Ramon
    Rubio-Terres, Carlos
    Rejas, Javier
    [J]. CLINICAL DRUG INVESTIGATION, 2006, 26 (08) : 447 - 457
  • [10] Muscarinic mechanisms of antipsychotic atypicality
    Bymaster, FP
    Felder, CC
    Tzavara, E
    Nomikos, GG
    Calligaro, DO
    Mckinzie, DL
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (07) : 1125 - 1143
12345678